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Long-term effects of cyclosporine A in Alport’s syndrome. renal involvement, renal insufficiency, neural hearing
Background. In 1991, our initial results of cyclosporine A loss, ocular abnormalities in the propositus or in a rela-
(CsA) administration in eight patients with Alport’s syndrome tive, and thickening of the glomerular basement mem-were published. A significant decrease in or disappearance
brane by electron microscopy with splitting and splinter-of proteinuria and apparently good tolerance to CsA were
ing of the lamina densa [2–10]. In our experience andobserved in all patients.
Methods. CsA administration has been maintained in these that of other authors, the presence of massive proteinuria
eight patients with the aim of obtaining further information is suggestive of a poor prognosis toward eventual renal
about the clinical course of the disease. The ages of these eight failure [1, 5, 7, 9–12].patients currently range from 15 to 27 years, and the mean
Eight patients described in our previous report [1] metduration of treatment is from 7 to 10 years (x 5 8.4 years).
these criteria and were selected to receive CsA treatmentResults. Renal function has remained stable, with no evalu-
able changes in serum creatinine levels compared with pre- (after parental consent had been obtained) because of
CsA treatment values. Proteinuria in all patients has either the presence of massive persistent proteinuria (.40 mg/
remained negative or are values far lower than pretreatment hr/m2). The disease was inherited from the mother inlevels. A second renal biopsy was performed in all patients
these eight selected patients, and a family history of renalafter five years of CsA administration. No aggravation of the
lesion present at the first biopsy or lesions typical of cyclo- involvement, neural hearing loss, and ocular abnormali-
sporine intoxication was observed. ties was verified in three generations of each family.
Conclusions. After a mean duration of 8.4 years and with The clinical features of these eight patients (mean age
no deterioration in renal function, we found possible beneficial
of 12.2 6 4.27 years) at the beginning of the study areeffects of the continued treatment of CsA in patients with
shown in Table 1. Arterial blood pressure was normalAlport’s syndrome who present evidence of progression to
renal insufficiency. in all patients except one, who required antihypertensive
therapy; seven patients had nerve deafness, and ocular
abnormalities were present in two. Creatinine clearance
In 1991, we published a study of the effects of cyclo- was normal in five patients and was moderately low in
sporine A (CsA) on proteinuria in eight patients with the other three; maximum urinary osmolarity was normal
Alport’s syndrome who presented with significant renal in six patients (1025.8 6 110.4 mOsm/kg) and decreased
involvement [1]. CsA was observed to have a marked in two patients with low creatinine clearance (patients
and sudden early reducing effect on proteinuria in all of 7 and 8; Table 1). Proteinuria was persistent and massive
them. Owing to the good patient tolerance to CsA and in all of them, ranging from 46 to 207 mg/hr/m2.
its persistence of action on proteinuria, administration Since the publication of our first article in 1991 [1],
has been continued up to the present for the purpose of CsA administration has been continued in these eight
obtaining more information about the potentially posi- patients. The initial total daily dose of CsA was 5 mg/
tive effects on the clinical course of the disease. kg/day (half of the dose being given every 12 hr), in the
search for the optimum dose required to maintain mean
levels of 82 6 13 ng/ml. The present age of these patientsMETHODS
ranges between 15 and 27 years, with a mean of 20.1The diagnosis of Alport’s syndrome was based on the
years, and the duration of CsA treatment currently rangespresence of hematuric nephropathy, a family history of
from 7 to 10 years. During these years of CsA treatment,
proteinuria, creatinine clearance, maximum urinary os-
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Proteinuria clearance MxU Osm
At onset At present mg/m2hr ml /min /1.73 m2 mOsm/kg
Age Age Length of At At At At At At
Patient Sex years Features years treatment onset present onset present onset present
1 M 8.8 N 16 7.2 126 0 110.9 106 953 898
2 M 8.4 N 15.4 7 46 0 92.5 98 1010 920
3 M 8.5 L 16.5 8 76 20.4 120.3 118 1212 991
4 M 13 N 21 7 70 43.6 128.6 99.4 1080 892
5 M 13 N, L 20 7 150 22 82 71.8 980 782
6 M 14 N 22 8 172 15.2 110.8 98 920 804
7 F 16 N 23 7 193 50.6 46 42.8 600 560
8 M 17 N, BP 27 10 207 20.1 43.2 38.4 400 410
Abbreviations are: N, nerve deafness; BP, hypertension; L, lenticonous. All presented with hematuria. Patient number 3 presented nerve deafness at 10 years of age.
dimetry. Creatinine clearance was calculated from the has appeared in case 3. Endogenous creatinine clearance
is normal in five patients (cases 1, 2, 3, 4, and 6) and hasserum creatinine concentration and rates of creatinine
excretion over a 24-hour period. Maximum urinary os- not varied noticeably in the remaining three cases (cases
5, 7, and 8) who had been in renal insufficiency prior tomolarity was measured after a 10-hour nocturnal hy-
dropenic period, and urine was investigated for a cryo- the start of the study (Fig. 2 and Table 1). In all of these,
macroscopic hematuria has persisted. Proteinuria hasscopic decrease. CsA was measured in total blood by
specific monoclonal radioimmunoassay. Liver function ranged from negative (cases 1 and 2) to 20.4 to 50.6 mg/
hr/m2 in the six remaining cases (Fig. 3 and Table 1).was regularly evaluated.
Two renal biopsies were performed in these eight pa- The maximum urinary osmolarity was maintained be-
tween 898 and 991 mOsm/kg in cases 1, 2, 3, and 4 andtients: the first before CsA administration and the second
in all patients after four to five years of CsA treatment. was decreased in the other four cases to 782, 824, 560,
and 410 mOsm/kg, respectively (Table 1).Hematoxylin-eosin, periodic acid-Schiff stain, Masson-
trichrome, and silver-methenamine were performed on The second biopsy, performed after four to five years
of CsA administration, revealed no worsening of therepresentative sections. Immunofluorescence stains and
electron microscopy were also performed. initial lesion, and vascular lesions suggestive that cyclo-
sporine intoxication, such as arteriolar hyalinosis, were
not observed. Thus, in cases with minimal mesangial
RESULTS proliferation, this continues to be the same, and focal
The first renal biopsy performed before the start of segmental sclerotic lesions are neither more diffuse nor
CsA administration showed the following features: mod- more generalized in the affected cases. No variations
erate or light focal and segmental glomerular hypercellu- have appeared on immunofluorescence study. Electron
larity on light microscopy in six patients; the remaining microscopy showed irregular thickening and discontinu-
two (patients 7 and 8; Table 1) had focal and segmental ity of the glomerular basement membrane, and splitting
lesions of the tuft due to marked thickening of the glo- and splintering of the lamina densa of the glomerular
merular basement membrane and mesangial matrix asso- basement membrane with the same intensity as observed
ciated with hyaline deposits and collagen of capillary in the first biopsy (Fig. 1).
loops. Immunofluorescence was negative in all patients.
Electron microscopy showed irregular thickening and
DISCUSSIONdiscontinuity of the glomerular basement membrane, as
well as the splitting and splintering of the lamina densa Our eight patients with Alport’s syndrome fulfill the
criteria proposed in the literature as suggestive of rapidof the glomerular basement membrane in all patients.
After 7 to 10 years of continued CsA treatment, the and precocious progression to end-stage renal disease:
gross hematuria, massive and persistent proteinuria, sen-clinico-analytical situation of these eight patients is as
follows: A good general status exists. Arterial blood pres- sorineural deafness with or without anterior lenticonus,
as well as diffuse thickening and multilamellation of thesure is normal in seven patients, and the remaining pa-
tient (case 8) continues to require two hypotensors for glomerular basement membrane [4, 7, 9, 10, 13, 14]. The
effect of CsA on proteinuria in these patients describedcontrol. Hypoacusia remains stable in three (cases 1, 2,
and 6), has worsened in four (cases 4, 5, 7, and 8), and in our previous report [1] still persists after a 7- to 10-
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Fig. 1. Electron micrograph of patient 5 (2nd renal biopsy). Irregular thickening of the glomerular basement membrane and splitting and splintering
of the lamina densa are shown (uranyl acetate 3 12,000).
year treatment period (proteinuria remains negative in the glomerular filtration rate in Alport’s syndrome (Fig.
2 and Table 1) [3, 4, 7, 9]. End-stage renal disease devel-two patients and is markedly reduced in the rest). Hypo-
acusia currently present in all patients has either re- ops in virtually all affected males with X-linked Alport’s
syndrome, and several authors have observed that themained stable or has worsened in three patients. Macro-
scopic hematuria persists in all of them (Table 1). Blood rate of progression to renal failure is fairly constant
among affected males within a particular family [7, 9,pressure remains the same, and maximum urinary osmo-
larity has not changed, except in patients 5 and 6, who 15–17]. Taking this into account and with all due reserve,
it was also interesting to compare the creatinine clear-presented maximum urinary osmolarity of 980 and 920
mOsm/kg prior to CsA and 782 and 804/kg after CsA, ance values of our eight patients with those of other
members of their respective families who had presentedrespectively. Endogenous creatinine clearance is stable
in all; it is of interest to note the findings in cases 5, 7, with renal insufficiency (Fig. 4 and Table 2). We were
able to verify a marked difference with respect to theand 8 in which decreased clearance values were observed
at the start of the study and have remained stable since chronological time of onset of the renal insufficiency in
favor of patients receiving CsA treatment. CsA levelsCsA treatment was started 7 to 10 years earlier, contrary
to what is normally observed in the natural evolution of throughout the study were 82 6 13 ng/ml. There were
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Fig. 2. Creatinine clearance values (ml/min/
1.73 m2) at onset and at present.
Fig. 3. Proteinuria values (mg/hr/m2) at onset
and at present.
no signs of hypertrichosis or gingival hypertrophy or by which CsA acts on proteinuria in these patients are
not clearly defined, although three basic types may beother more serious side-effects (such as opportunistic
infections, malignancies, and so forth). The other ele- accepted: (a) renal vasoconstriction (renal hemodynamic
changes); (b) direct action on the permselectivity of thement to be assessed in these eight patients was the lack
of evolution of the histologic lesion or lesions related to glomerular basement membranes, particularly on the
electrochemical barrier that repels anionic albumin mol-CsA effects. There was no aggravation of the existent
glomerular lesion or an increase in interstitial fibrosis. ecules; and (c) the immunological nature that involves
lymphokine secretion inhibition [23–36]. All of theseThe lesion of the glomerular basement membrane per-
sists in all cases, with the same characteristics in each different actions would slow down disease progression
with no variation in the basic type IV collagen lesion.[14, 18, 19].
Angiotensin-converting enzyme inhibitors do not re- Kashtan recently affirmed that a demonstrably effec-
tive method of slowing down the progression of Alport’sduce proteinuria in patients with Alport’s syndrome as
CsA proved to do in our study [1, 20–22]. Mechanisms nephropathy does not exist [13]. However, because mes-
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Fig. 4. Comparative creatinine clearance val-
ues in probands and relatives at similar ages.
Only the age at end-stage renal failure is
shown for relatives of cases 6 and 7. Symbols
are: (C—) probands; (•· – · ) brother; (•– – )
cousin.
Table 2. Comparative creatinine clearance values in probands and suggestive or demonstrative of progression to chronic
relatives at similar ages
renal insufficiency are observed. It may be concluded
At onset At present that CsA delays progression to end-stage renal failure
Family Patient Age years CCr Age years Ccr in these patients. However, further studies are required
before the general administration of CsA can be recom-1 proband 8.8 110.9 17 106
brother 9.0 100.2 17 23.2 mended in Alport’s syndrome for those patients with
2 proband 8.4 92.5 15.4 98 adverse prognostic indicators.
brother 9.1 98.4 16 42.2
3 proband 8.5 120.3 16.5 118
cousin 10 117.4 19 23.7 ACKNOWLEDGMENTS
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